Beranda › Kanker Esofagus › Pennsylvania › Pittsburgh
Uji klinis Kanker Esofagus di Pittsburgh, PA
15 studi untuk Kanker Esofagus mencari peserta di lokasi sekitar Pittsburgh (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
Menerima pesertaFase 1/2
- UPMC Hillman Cancer Center-UPMC ( Site 4904), Pittsburgh
Distance-Based Exercise to Preserve Function and Prevent Disability
Menerima peserta
- UPMC Hillman Cancer Center, Pittsburgh
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Menerima pesertaFase 1
- University of Pittsburgh Medical Center, Pittsburgh
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Menerima pesertaFase 1/2
- Allegheny Health Network, Pittsburgh
SKL35501 With SKL35502 Imaging in Adults With NTSR1 Positive Advanced Solid Tumors
Menerima pesertaFase 1
- UPMC Hillman Cancer Center, Pittsburgh
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
Menerima pesertaFase 3
- Research Site, Pittsburgh
- Research Site, Pittsburgh
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
Menerima pesertaFase 1/2
- UPMC Hillman Cancer Center-UPMC ( Site 8904), Pittsburgh
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
Menerima pesertaFase 1/2
- UPMC Hillman Cancer Center-UPMC ( Site 6904), Pittsburgh
Lead-212 PSV359 Therapy for Patients With Solid Tumors
Menerima pesertaFase 1/2
- University of Pittsburgh Medical Center, Pittsburgh
Impact of Prehabilitation in Oncology Via Exercise- Esophageal (IMPROVE-Esophageal)
Menerima peserta
- UPMC Hillman Cancer Center, Pittsburgh
Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
Menerima pesertaFase 2
- UPMC Hillman Cancer Center, Pittsburgh
Esophageal Cancer Risk Registry
Menerima pesertaStudi observasional
- Department of Cardiothoracic Surgery, Pittsburgh
Outcomes After Esophagectomy With a Focus on Minimally Invasive Esophagectomy and Quality of Life
Menerima pesertaStudi observasional
- University of Pittsburgh Medical Center - Department of Cardiothoracic Surgery, Pittsburgh
- UPMC - Hillman Cancer Center, Pittsburgh
The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
Menerima pesertaStudi observasional
- Allegheny Health Network, Pittsburgh
Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors
Menerima pesertaFase 1
- AHN West Penn Hospital, Pittsburgh
Uji klinis Kanker Esofagus di kota lain
- Houston, TX36 studi
- Boston, MA23 studi
- New York City, NY22 studi
- Nashville, TN19 studi
- St. Louis, MO17 studi
- Los Angeles, CA15 studi
- Baldwin Park, CA14 studi
- Grand Rapids, MI14 studi
- Philadelphia, PA13 studi
- San Antonio, TX12 studi
- Rochester, MN11 studi
- Arlington, VA11 studi
Studi lain di Pittsburgh
- Kanker Paru Non-Sel Kecil48 studi
- Kanker (semua jenis)41 studi
- Kanker Payudara39 studi
- Kanker Kolorektal32 studi
- Kanker Metastatik31 studi
- Melanoma31 studi
- Kanker Ovarium30 studi
- Kanker Endometrium23 studi
- Kanker Prostat23 studi
- Kanker Paru23 studi
- Karsinoma Sel Skuamosa Kepala dan Leher22 studi
- Stroke22 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.